AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39007065 — intervention group
Group type: EXPERIMENTAL
Intervention: VPC regimen
Number of subjects: 34
Study 39007066 — intervention group
Group type: EXPERIMENTAL
Intervention: MIL62 combined with lenalidomide
Number of subjects: 54
Study 39007552 — intervention group
Group type: EXPERIMENTAL
Intervention: TCAR with MicroNET-covered neuroprotective stent (CGuard)
Number of subjects: 106
Study 39007556 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency mechanical reperfusion (EMR) treatment
Number of subjects: 101
Study 39007556 — intervention group
Group type: COMPARATOR
Intervention: EMR-untreated patients
Number of subjects: 101
Study 39007703 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy combined with Cognitive-Behavioral Therapy for eating disorders (TF-CBT-WB)
Number of subjects: 30
Study 39007830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0
Study 39007830 — intervention group
Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT; OAC plus P2Y12 inhibitor)
Number of subjects: 0
Study 39007836 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D levels
Number of subjects: 0
Study 39007836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c levels
Number of subjects: 0
Study 39007836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 levels
Number of subjects: 0
Study 39007915 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF10 deletion
Number of subjects: 0
Study 39007915 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF10 binding to atrophy genes
Number of subjects: 0
Study 39007942 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin plus miltefosine (Arm 1)
Number of subjects: 0
Study 39007942 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B plus miltefosine (Arm 2)
Number of subjects: 0
Study 39007942 — intervention group
Group type: COMPARATOR
Intervention: Low IFN-γ, TNF and IL-1β before treatment (Arm 2)
Number of subjects: 0
Study 39007942 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1 treatment in patients with low IFN-γ production at D0
Number of subjects: 0
Study 39007997 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 32
Study 39007997 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 32
Study 39007997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 39008026 — intervention group
Group type: EXPERIMENTAL
Intervention: LD EC-ASA
Number of subjects: 47
Study 39008026 — intervention group
Group type: EXPERIMENTAL
Intervention: LD PL-ASA
Number of subjects: 47
Study 39008026 — intervention group
Group type: COMPARATOR
Intervention: Bayer
Number of subjects: 47
Study 39008067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge of RLT (Radioligand Therapy)
Number of subjects: 47
Study 39008067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge of RLT
Number of subjects: 47
Study 39008067 — intervention group
Group type: EXPERIMENTAL
Intervention: Second and third rechallenge series of RLT
Number of subjects: 47
Study 39008191 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item sleep disturbance numerical rating scale (SD NRS)
Number of subjects: 0
Study 39008191 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-item Subject Sleep Diary (SSD)
Number of subjects: 0
Study 39008208 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (Arm 1)
Number of subjects: 126
Study 39008208 — intervention group
Group type: COMPARATOR
Intervention: mFOLFIRINOX and hypofractionated radiotherapy (Arm 2)
Number of subjects: 126
Study 39008208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 126
Study 39008236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (pooled doses of 5, 10, and 15 mg)
Number of subjects: 1428
Study 39008236 — intervention group
Group type: COMPARATOR
Intervention: Insulin Lispro
Number of subjects: 1428
Study 39008317 — intervention group
Group type: EXPERIMENTAL
Intervention: STOMP intervention (Skills to Manage Pain)
Number of subjects: 278
Study 39008317 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 278
Study 39008350 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world physical behavior measures derived from wearable accelerometers
Number of subjects: 86
Study 39008350 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise test estimating aerobic fitness (predicted submaximal oxygen uptake)
Number of subjects: 86
Study 39008350 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported well-being and physical function assessments
Number of subjects: 86
Study 39008481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg) and WT1/DC vaccination (8-10 x 106 cells/vaccination) in combination with standard-of-care chemotherapy (cisplatinum 75mg/m2 and pemetrexed 500mg/m2)
Number of subjects: 15
Study 39008542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (CLAD) tablets
Number of subjects: 240
Study 39008826 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal estradiol (E2) pretreatment
Number of subjects: 324
Study 39008858 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer screening decision aid (DA) intervention
Number of subjects: 495
Study 39008947 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 16
Study 39008947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 39008999 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine plus tenofovir alafenamide (200/300 mg)
Number of subjects: 5399
Study 39008999 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine plus tenofovir disoproxil fumarate (200/25 mg)
Number of subjects: 5399
Study 39009040 — intervention group
Group type: EXPERIMENTAL
Intervention: R-BAC + DA (dornase alfa)
Number of subjects: 39
Study 39009040 — intervention group
Group type: COMPARATOR
Intervention: R-BAC (control group)
Number of subjects: 39
Study 39009085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 2 mg/day
Number of subjects: 150
Study 39009085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulevirtide 10 mg/day
Number of subjects: 150
Study 39009085 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 150
Study 39009116 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein > 2 mg/l
Number of subjects: 62
Study 39009116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein levels (<1200 mmol/l)
Number of subjects: 62
Study 39009116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein levels
Number of subjects: 62
Study 39009116 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c >7%
Number of subjects: 62
Study 39009116 — intervention group
Group type: EXPERIMENTAL
Intervention: HgAbc1 >7%
Number of subjects: 62
Study 39009130 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - stainless steel
Number of subjects: 297
Study 39009130 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - nitinol
Number of subjects: 297
Study 39009130 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac branch devices (IBDs) - overall
Number of subjects: 297
Study 39009312 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (up to a 21 mg daily dose over 12 weeks)
Number of subjects: 29
Study 39009356 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil concentrate (KOC) 4 g/day for 24 weeks
Number of subjects: 78
Study 39009356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable oil mixture)
Number of subjects: 78
Study 39009368 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid prescriptions at emergency department discharge
Number of subjects: 2240
Study 39009368 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller, cause-specific opioid prescriptions
Number of subjects: 2240
Study 39009453 — intervention group
Group type: EXPERIMENTAL
Intervention: AneuFix injectable polymer during endovascular aneurysm repair (EVAR)
Number of subjects: 25
Study 39009709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna) treatment for 1 year
Number of subjects: 0
Study 39009764 — intervention group
Group type: EXPERIMENTAL
Intervention: High consistent self-monitoring group
Number of subjects: 150
Study 39009764 — intervention group
Group type: COMPARATOR
Intervention: Low-decreasing self-monitoring group
Number of subjects: 150
Study 39009776 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 53
Study 39009776 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 53
Study 39009776 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device data
Number of subjects: 53
Study 39009785 — intervention group
Group type: EXPERIMENTAL
Intervention: LAWT-guided radiofrequency ablation
Number of subjects: 109
Study 39009804 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks
Number of subjects: 125
Study 39009804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 39009990 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait trainer Walkbot combined with physiotherapy (4 sessions per week of 40 min for 5 weeks)
Number of subjects: 23
Study 39009990 — intervention group
Group type: COMPARATOR
Intervention: Isolated physiotherapy
Number of subjects: 23
Study 39010013 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg position duration
Number of subjects: 25
Study 39010089 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning group
Number of subjects: 0
Study 39010089 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning group
Number of subjects: 0
Study 39010098 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Approach to Improved Nutritional support for patients with cancer (GAIN)
Number of subjects: 0
Study 39010098 — intervention group
Group type: COMPARATOR
Intervention: Current nutritional support practices
Number of subjects: 0
Study 39010160 — intervention group
Group type: EXPERIMENTAL
Intervention: EBQI-IC (individual coaching)
Number of subjects: 16
Study 39010160 — intervention group
Group type: EXPERIMENTAL
Intervention: EBQI-LC (learning collaborative)
Number of subjects: 16
Study 39010160 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 39010171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray 0.2 µg/kg
Number of subjects: 150
Study 39010171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine nasal spray 0.5 µg/kg
Number of subjects: 150
Study 39010171 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray (Control)
Number of subjects: 150
Study 39010208 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt closure of external ventricular drain (EVD)
Number of subjects: 244
Study 39010208 — intervention group
Group type: COMPARATOR
Intervention: Gradual weaning of external ventricular drain (EVD)
Number of subjects: 244
Study 39010232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal affective cognitive training (PACT)
Number of subjects: 292
Study 39010232 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 292
Study 39010232 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT
Number of subjects: 292
Study 39010232 — intervention group
Group type: COMPARATOR
Intervention: CAU
Number of subjects: 292
Study 39010659 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon resting angle (ATRA) symmetry at 2 months
Number of subjects: 35
Study 39010659 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegner score at 2 and 12 months
Number of subjects: 35
Study 39010659 — intervention group
Group type: EXPERIMENTAL
Intervention: Achilles tendon total rupture score (ATRS) at 12 months
Number of subjects: 35
Study 39010683 — intervention group
Group type: EXPERIMENTAL
Intervention: Kavalactones
Number of subjects: 15
Study 39010683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 39010708 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole treatment during inflammation
Number of subjects: 39
Study 39010708 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or high CRP levels (>50 mg/L)
Number of subjects: 39
Study 39010708 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis with and without inflammation
Number of subjects: 39
Study 39010708 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole plasma concentrations during inflammation
Number of subjects: 39
Study 39010748 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to deal with distractions and conflicting situations in activities of daily living after TBI
Number of subjects: 0
Study 39010780 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based parent school program (10-week duration, including five website modules, five online interactive group trainings, and counseling)
Number of subjects: 48
Study 39010780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 48
Study 39010780 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based parent school program
Number of subjects: 48
Study 39011096 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antimicrobial plus RB-PDT
Number of subjects: 0
Study 39011096 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobial plus sham RB-PDT
Number of subjects: 0
Study 39011360 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH Stroke Scale (NIHSS)
Number of subjects: 384
Study 39011360 — intervention group
Group type: COMPARATOR
Intervention: Intracerebral hemorrhage score (ICH score)
Number of subjects: 384
Study 39011819 — intervention group
Group type: EXPERIMENTAL
Intervention: Frictionless group using closing T-loops for en-masse retraction
Number of subjects: 30
Study 39011819 — intervention group
Group type: COMPARATOR
Intervention: Friction group using NiTi coil springs
Number of subjects: 30
Study 39011819 — intervention group
Group type: COMPARATOR
Intervention: Friction group
Number of subjects: 30
Study 39011819 — intervention group
Group type: EXPERIMENTAL
Intervention: Frictionless group
Number of subjects: 30
Study 39011819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 39011963 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia (PE) children
Number of subjects: 267
Study 39011963 — intervention group
Group type: COMPARATOR
Intervention: Non-preeclampsia (non-PE) children
Number of subjects: 267
Study 39012090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmanogepix (FMGX)
Number of subjects: 0
Study 39012221 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DXd (Trastuzumab deruxtecan)
Number of subjects: 0
Study 39012226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide treatment, dosage and duration not specified
Number of subjects: 0
Study 39012226 — intervention group
Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study 39012233 — intervention group
Group type: EXPERIMENTAL
Intervention: H2O2 and HA
Number of subjects: 114
Study 39012233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 39012233 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 114
Study 39012250 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging with normalized join-count analysis for emphysema progression
Number of subjects: 0
Study 39012250 — intervention group
Group type: COMPARATOR
Intervention: Baseline CT images
Number of subjects: 0
Study 39012500 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Number of subjects: 181
Study 39012630 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics-informed intervention bundle including default scheduling of postpartum PCP appointments and tailored messages
Number of subjects: 360
Study 39012630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 360
Study 39012630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 360
Study 39012717 — intervention group
Group type: EXPERIMENTAL
Intervention: Setrusumab 20 mg/kg
Number of subjects: 110
Study 39012717 — intervention group
Group type: EXPERIMENTAL
Intervention: Setrusumab 8 mg/kg
Number of subjects: 110
Study 39012717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 39012722 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS webSTAIR
Number of subjects: 178
Study 39012722 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 178
Study 39012843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical composition (yeast β-glucan, prebiotics, minerals, and silymarin)
Number of subjects: 22
Study 39012843 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 39012877 — intervention group
Group type: EXPERIMENTAL
Intervention: treadmill + Gamified Virtual Reality Environment (GVRE) + tDCS training group
Number of subjects: 78
Study 39012877 — intervention group
Group type: EXPERIMENTAL
Intervention: treadmill + GVRE training group
Number of subjects: 78
Study 39012877 — intervention group
Group type: COMPARATOR
Intervention: treadmill training group
Number of subjects: 78
Study 39012930 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized prescription of pacing (PPoP) for 6 months
Number of subjects: 17
Study 39012930 — intervention group
Group type: COMPARATOR
Intervention: Backup pacing
Number of subjects: 17
Study 39012942 — intervention group
Group type: EXPERIMENTAL
Intervention: LA HFpEF shape score
Number of subjects: 68
Study 39012942 — intervention group
Group type: EXPERIMENTAL
Intervention: LA roof dilation
Number of subjects: 68
Study 39012942 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall LA enlargement
Number of subjects: 68
Study 39012942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular hospitalization
Number of subjects: 68
Study 39012946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperglycemia with low HDL cholesterol
Number of subjects: 1200
Study 39012946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperglycemia with high systemic blood pressure
Number of subjects: 1200
Study 39012946 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 1200
Study 39012946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid plaque progression
Number of subjects: 1200
Study 39013131 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 42
Study 39013133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome+ sequencing (Helix Inc, San Mateo, CA)
Number of subjects: 44306
Study 39013194 — intervention group
Group type: EXPERIMENTAL
Intervention: Dashboard plus discharge checklist
Number of subjects: 260
Study 39013194 — intervention group
Group type: COMPARATOR
Intervention: Dashboard
Number of subjects: 260
Study 39013194 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation
Number of subjects: 260
Study 39013265 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 255
Study 39013265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 39013470 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic CD19-targeted CAR-T therapy
Number of subjects: 3
Study 39013643 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive spine surgery (MISS)
Number of subjects: 126
Study 39013643 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior spine fusion
Number of subjects: 126
Study 39013644 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological autopsy method integrating anthropological and psycholinguistic approaches
Number of subjects: 0
Study 39013644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory multimethod strategy combining epidemiological, anthropological, psycholinguistic, and psychological methods
Number of subjects: 0
Study 39013644 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiautomated analysis of the discourse of relatives bereaved by suicide
Number of subjects: 0
Study 39013644 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results and perspectives communicated to bereaved relatives
Number of subjects: 0
Study 39013653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Tegaderm Antimicrobial IV Advanced Securement dressing
Number of subjects: 2924
Study 39013653 — intervention group
Group type: COMPARATOR
Intervention: Standard polyurethane dressing
Number of subjects: 2924
Study 39013654 — intervention group
Group type: EXPERIMENTAL
Intervention: mifepristone (Korlym)
Number of subjects: 1000
Study 39013654 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study 39013870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 61
Study 39013870 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (carboplatin plus paclitaxel)
Number of subjects: 61
Study 39013886 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoAdjuvant ChemoTherapy (NACT) + Pembrolizumab (P)
Number of subjects: 0
Study 39013886 — intervention group
Group type: COMPARATOR
Intervention: NeoAdjuvant ChemoTherapy (NACT)
Number of subjects: 0
Study 39014136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP quartile Q1 (<8 mg/L)
Number of subjects: 772
Study 39014136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP quartile Q2 (8-28 mg/L)
Number of subjects: 772
Study 39014136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP quartile Q3 (>28-69 mg/L)
Number of subjects: 772
Study 39014136 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP quartile Q4 (>69 mg/L)
Number of subjects: 772
Study 39014267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB
Number of subjects: 49
Study 39014267 — intervention group
Group type: COMPARATOR
Intervention: Healthy Lifestyle attention control
Number of subjects: 49
Study 39014316 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical enlargement to 35#/0.04 and 40#/0.04 for Group A (mesial and distal canals respectively)
Number of subjects: 25
Study 39014316 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical enlargement to 40#/0.04 and 45#/0.04 for Group B (mesial and distal canals respectively)
Number of subjects: 25